Kazama T, Katayama T, Umeda K, Akiya T, Nakada T
Hinyokika Kiyo. 1986 Feb;32(2):201-5.
Ten patients with reactivated stage D prostatic cancer were treated with the combination therapy of vincristine, ifosfamide and peplomycin (VIP therapy). This treatment gave a good relief of bone pain in 4 out of 8 patients (50%) and improvement of dysuria in 2 out of 6 patients (33%), but objective responses of primary and metastatic lesions were poor. The over-all response rate was 20% by Karnofsky's category of response, 10% by the response criteria of Shida et al., 50% by National Prostatic Cancer Project criteria in the United States and 10% by the response criteria of Koyama and Saito's group. The toxicity of VIP therapy was mild to moderate except for hepatic insufficiency shown in one case.
10例复发的D期前列腺癌患者接受了长春新碱、异环磷酰胺和培普利霉素联合治疗（VIP疗法）。该治疗使8例患者中的4例（50%）骨痛得到显著缓解，6例患者中的2例（33%）排尿困难有所改善，但原发灶和转移灶的客观缓解情况较差。根据卡诺夫斯基反应分类，总体缓解率为20%；按照志田等人的反应标准为10%；按照美国国家前列腺癌项目标准为50%；按照小山和斋藤小组的反应标准为10%。除1例出现肝功能不全外，VIP疗法的毒性为轻度至中度。
